Brief: Lipocine Announces Continued Commercialization Of Tlando
02/02/2024 13:36
Feb 2 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE ANNOUNCES CONTINUED COMMERCIALIZATION OF TLANDO®
THROUGH VERITY PHARMACEUTICALS
* LIPOCINE INC - COMMERCIALIZATION OF TLANDO® IN U.S. HAS
BEEN
TRANSITIONED TO ITS LICENSEE VERITY PHARMA, EFFECTIVE FEBRUARY
1, 2024
Source text for Eikon: ID:nPn86Ts7Sa
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy